Efficacy and safety of Xiyanping injection in the treatment of COVID‐19: A multicenter, prospective, open‐label and randomized controlled trial

Abstract

Xiyanping (XYP) is a Chinese herbal medicine used in the clinic to treat respiratory infection and pneumonia. Recent evidence identified XYP as a potential inhibitor of severe acute respiratory syndrome coronavirus 2, implying XYP as a possible treatment for the coronavirus disease 2019 (COVID‐19). Here, we conducted a prospective, multicenter, open‐label and randomized controlled trial to evaluate the safety and effectiveness of XYP injection in patients with mild to moderate COVID‐19. We consecutively recruited 130 COVID‐19 patients with mild to moderate symptoms from five study sites, and randomized them in 1:1 ratio to receive XYP injection in combination with standard therapy or receive standard supportive therapy alone. We found that XYP injection significantly reduced the time to cough relief, fever resolution and virus clearance. Less patients receiving XYP injection experienced disease progression to the severe stage during the treatment process. No severe adverse events were reported during the study. Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID‐19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID‐19 patients at different disease stages.

Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review

“…Twenty-four RCTs reported the generation of random sequences, of which three RCTs [ 12 , 26 , 29 ] described the performance of allocation concealment. Two RCTs [ 12 , 29 ] blinded participants and researchers as well as outcome evaluators. Twenty-nine RCTs completely reported the data of each primary outcome, including lost to follow-up and withdrawal.…”

“…The meta-analysis of 7 RCTs [ 11 , 12 , 16 , 18 , 19 , 22 , 23 ] demonstrated that TCM could observably lessen the proportion of patients progressing to severe cases [RR = 0.45, 95% CI (0.29, 0.68), I 2 = 0%, P = 0.0002] (Fig. 3 ).…”

Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild COVID-19: a retrospective cohort study

“…Eligible participants were at least 18 years old and diagnosed with COVID-19 infection by Real-Time Polymerase Chain Reaction (RT-PCR) test. According to the definition of mild COVID-19 used in previous work (Zhang et al, 2021), we included only patients who had normal chest radiography by the time of hospital admission. In contrast, individuals who did not have chest radiography results received antiviral drugs (i.e., favipiravir) or received systemic corticosteroids on the first day of admission were excluded.…”

Andrographolide: A Herbal-Chemosynthetic Approach for Enhancing Immunity, Combating Viral Infections, and Its Implication on Human Health

“…Li et al [55] using network bioinformatics analysis based on clinical knowledge prioritized AGL (among 30 candidates) as a potentially effective COVID-19 repurposable drug. Interestingly, Zhang et al [56] in his clinical trial showed that injection with Xiyanping (XYP), a Chinese herbal compound (composed of 9-dehydro-17-hydro-andrographolide and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate) improves and recovers COVID-19 patients having mild and moderate symptoms. Today, advancement with the laboratory and pharmacological studies focusing on AGL as a herbal bio-active compound has accelerated huge verified data with scientific outputs establishing its potential immune protective role in combating such viral outbreaks.…”